Adalimumab: In psoriatic arthritis

Drugs

Volumn 66, Issue 11, 2006, Pages 1487-1496

  Simpson, Dene ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERSTITIAL COLLAGENASE; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTEIN P55; PROTEIN P75; STROMELYSIN; TUMOR NECROSIS FACTOR;

BONE RADIOGRAPHY; CLINICAL TRIAL; DISABILITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; JOINT DESTRUCTION; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33747329055     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666110-00008     Document Type: Review

References (33)

1. Gladman DD. Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review. Drugs 2005; 65 (9): 1223-38
2. Kyle S, Chandler D, Griffiths CE, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 2005 Mar; 44 (3): 390-7
3. Griffiths CE, Iaccarino L, Naldi L, et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006 Jan; 24 Suppl. 40: S72-8
4. Finucane KA, Archer CB. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus. Clin Exp Dermatol 2005; 30 (2): 201-4
5. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52 (1): 1-19
6. Prasad R, Gladman D. Current and investigational treatment of psoriatic arthritis. Expert Opin Invest Drugs 2004; 13 (2): 139-50
7. Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004 Jul; 63 (7): 755-8
8. Ruderman EM, Tambar S. Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. Dermatol Clin 2004; 22 (4): 477-86
9. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. Biodrugs 2005; 19 (1): 47-57
10. Bang LM, Keating GM. Adalimumab; a review of its use in rheumatoid arthritis. Biodrugs 2004; 18 (2): 121-39
11. Mease PJ. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther 2005 Nov; 5 (11): 1491-504
12. Kavanaugh A, Greenwald M, Zizac T, et al. Immune response is not affected by adalimumab therapy [abstract no. THU0196]. Ann Rheum Dis 2003; 62 Suppl. 1: 169
13. Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and anti-TNF-α agents. Ann N Y Acad Sci 2005; 1051 (559-569)
14. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004 May; 63 (5): 508-16
15. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003 Jan; 48 (1): 35-45
16. Abbott Laboratories. Humira® (adalimumab): prescribing information, 2005 Oct
17. Velagapudi RB, Noertersheuser PA, Awni WM, et al. Effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (HUMIRA™, Abbott) following a single intravenous injection [abstract no. 258]. Arthritis Rheum 2003; 48 (9 Suppl.): S141
18. Awni WA, Cascella P, Napoleaon A, et al. Steady-state pharmacokinetics (PK) of adalimumab (HUMIRA tm, Abbott) following 40mg subcutaneous (sc) injection every other week (eow) in rheumatoid arthritis (RA) patients with or without methotrexate (MTX) background therapy [abstract no. 255]. Arthritis Rheum 2003; 48 Suppl. 9: S140
19. Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol 2005; 32 Suppl. 74: 13-8
20. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Sem Arthritis Rheum 2005; 34 (5 Suppl.): 12-8
21. van de Putte LBA, Salfield J, Kaymakcalan Z. TNF (a)-inhibition in the treatment of rheumatoid arthritis. In: Moreland LW, Emery P, editors. Adalimumab. London: Martin Dunitz, 2003: 71-93
22. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005 Oct; 52 (10): 3279-89
23. Genovese MC, Mease PJ, Thomson GTD, et al. Adalimumab efficacy in patients with psoriatic arthritis who failed prior DMARD therapy [abstract no. FRI0187]. Ann Rheum Dis 2005; 64 Suppl. III: 313. EULAR Annual European Congress of Rheumatism; 2005 8-11 Jun; Vienna
24. Mease PJ, Sharp JT, Ory P, et al. Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: results from ADEPT [abstract no. FRI0212]. Annual European Congress of Rheumatology, Jun 8-11 2005, Vienna. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 320
25. Gladman DD, Mease PJ, Emery P, et al. Adalimumab treatment effects on quality of life in patients with psoriatic arthritis: results from ADEPT [abstract no. FRI0203]. Ann Rheum Dis 2005; 64 Suppl. III: 317. EULAR Annual European Congress of Rheumatology; 2005 Jun 8-11; Vienna
26. Guh D, Bansback NJ, Nosyk B, et al. Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira (Rm)) [abstract no. FRI0476]. Ann Rheum Dis 2005: 64 Suppl. III: 401. ISPOR 8th Annual European Congress; 2005 6-8 Nov; Florence
27. Kavanaugh AF, Ritchlin CT, Malaise MG, et al. Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: results from ADEPT [abstract no. FRI0227]. Ann Rheum Dis 2005; 64 Suppl. III: 325. EULAR Annual European Congress of Rheumatology; 2005 Jun 8-11; Vienna
28. Mease PJ, Gladman DD, Ritchlin CT, et al. Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT [abstract no. 500]. Arthritis Rheum 2005; 52 (Suppl. 9): 215. Annual Scientific Meeting of the American College of Rheumatology; 2005 Nov 12-17; San Diego
29. Mease P, Gladman D, Ritchlin C, et al. Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial [abstract no. P2864]. J Am Acad Dermatol 2006; 54 Suppl. 1: AB214
30. Gladman D, Mease P, Kavanaugh A, et al. Adalimumab is efficacious in treating skin disease in psoriatic arthritis: subanalysis of moderate versus severe psoriasis in the ADEPT trial [abstract no. P40]. J Am Acad Dermatol 2006: 54 Suppl. 1: AB10-11
31. Anis AH, Guy D, Melilli LE. Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira Rm) [abstract no. PAR12]. Value Health 2005; 8: A27. Plus poster presented at the 8th International Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2005 Nov 6-8; Florence
32. Mease PJ, Antoni CE, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 2): ii49-54
33. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies [published erratum appears in JAMA 2006; 295 (21): 2482]. JAMA 2006; 295 (19): 2275-85